The nicotinamide riboside heart failure trial found that the study capsules were generally tolerated over 12 weeks. They raised blood NAD+, a helper molecule cells need for energy-related reactions. The 30-person trial did not establish better heart function, fewer hospital stays or longer life.
Nicotinamide riboside, shortened to NR, is an ingredient the body uses to make NAD+. NAD+ stands for nicotinamide adenine dinucleotide. Researchers tested swallowed NR, rather than NAD+ injections.
What did the nicotinamide riboside heart failure trial ask?
The question was whether people with stable heart failure could tolerate NR while researchers watched for health problems. Wang and colleagues published the study in JACC: Basic to Translational Science in 2022.
This was an added treatment alongside participants' heart medicines. It wasn't a replacement for them.
Who joined, and for how long?
Researchers at the University of Washington randomly assigned 20 people to NR and 10 to placebo, matching capsules without NR. Participants and investigators didn't know the assignments.
Participants were 37–81 years old; seven were women. All had heart failure with reduced ejection fraction: weakened pumping by the heart's main chamber. Ejection fraction is the percentage of blood that chamber pumps out with each beat. The study required a measurement of 40% or less.
People with recent heart-related hospital stays or procedures, significant kidney or liver problems, or pregnancy were excluded. These were stable outpatients, rather than people receiving emergency heart care.
Treatment lasted 12 weeks. The study gradually increased NR to 1,000 mg twice daily for the final nine weeks. That describes the experiment, rather than a treatment schedule for readers.
What was measured, and why does the molecule matter?
The registry, NCT03423342, names health problems arising during treatment as the primary outcome, meaning the main planned assessment. Additional measurements included blood NAD, abnormal laboratory results and energy use in immune cells, which help defend the body. Walking distance and heart ultrasound measurements were exploratory: early checks for possible effects.
A precursor is an ingredient used to make another molecule. NR is a precursor; NAD+ is the molecule made from it. Our history of NAD explains that connection. Giving the ingredient and giving NAD+ itself ask different questions about absorption, processing and safety. The NR trial cannot supply results for a compounded NAD+ preparation.
The result: blood NAD rose, without a demonstrated heart benefit
Whole-blood NAD approximately doubled with NR. In the full paper, the average change was about 30 micromoles per liter, a blood-concentration unit, versus −0.3 with placebo. Paired blood measurements were available for 19 NR participants and 10 placebo participants.
Larger NAD increases were linked with greater energy use in immune cells and lower activity of NLRP3, an inflammation-related gene. Those measurements came from blood cells, not heart muscle.
Walking distance, quality of life and heart ultrasound results did not pass the study’s statistical test for a difference between treatments. The sample was too small to determine whether a meaningful benefit exists. A higher blood marker alone doesn't answer whether breathing, daily activity or survival improves.
What did the side-effect table show?
The paper counted 63 adverse events, meaning reported health problems, in the NR group and 34 with placebo. These are event totals; one person could have several. Researchers detected no significant difference between groups.
The most common categories in the paper's Table 3, counted as people affected:
| Reported problem category | NR, out of 20 | Placebo, out of 10 |
|---|---|---|
| General symptoms and administration-site problems | 9 (45%) | 4 (40%) |
| Nervous-system problems | 6 (30%) | 5 (50%) |
| Infections | 6 (30%) | 5 (50%) |
| Muscle, joint or connective-tissue problems | 6 (30%) | 1 (10%) |
| Stomach or bowel problems | 3 (15%) | 2 (20%) |
| Heart-related problems | 3 (15%) | 1 (10%) |
| Breathing and chest problems | 3 (15%) | 3 (30%) |
| Out-of-range laboratory results | 1 (5%) | 1 (10%) |
Reporting a problem doesn't establish that NR caused it. One participant stopped study medication because of stomach or bowel intolerance. The paper describes one serious event on treatment, a placebo participant's hospitalization involving worsening heart failure and pancreatic inflammation.
The registry separately lists serious events over 16 weeks in one NR participant and two placebo participants. Its longer reporting window differs from the paper's treatment period; the accounts aren't interchangeable. Neither establishes long-term safety.
These figures belong to swallowed NR. They cannot estimate side effects of NAD+ itself or of a compounded NAD+ preparation. Changing the molecule or delivery route calls for separate safety evidence.
What did outside reviewers and follow-up research add?
In an accompanying editorial, Michael Sack emphasized that the study wasn't large enough to test effectiveness. Direct effects on heart tissue remained a question. A follow-up study, NCT04528004, examines heart tissue collected during surgery to implant a mechanical heart pump; its registry has no posted results.
As of November 5, 2026, the day this article was written, an October 30 Cardiovascular Research study adds animal evidence. Its abstract reports improved heart relaxation in aged male mice given NR or dihydronicotinamide riboside (NRH), a related precursor, but no response in aged females. That finding leaves the human heart-failure question open.
Later NAD+ research asks a different question
As of November 5, 2026, the day this article was written, a separate October 30 trial in American Journal of Cardiovascular Drugs reports results in 120 people after a heart attack. They received NAD+ into a vein or placebo alongside standard care after a procedure to reopen an artery.
At 30 days, ejection fraction averaged 56.32% with NAD+ versus 53.37% with placebo, a modest difference the authors reported as statistically significant. Serious heart and circulation events over six months didn't differ significantly. As of November 20, 2026, the day this update was written, the paper reports five cardiovascular deaths during six-month follow-up, three in the NAD+ group and two with placebo; the investigators considered none related to the study intervention. That study excluded chronic heart failure and tested a different molecule and preparation from oral NR. Its findings don't establish results for compounded NAD+.
The NAD IV study guide covers infusion evidence, including a 2025 trial in people with heart failure. A shared connection to NAD biology doesn't make the preparations interchangeable.
What this means for a treatment discussion
The same boundary applies across illnesses. The NR Parkinson's trial concerns another patient group; its results cannot settle heart-failure treatment.
As of November 5, 2026, the day this article was written, the European Society of Cardiology's heart-failure guidance, published August 28, keeps established medicines central. Its official recommendations support continuing foundational treatment, the medicines underpinning cardiac care. The NR pilot gives no basis for replacing that care.
Compounded NAD+ is not FDA-approved. As FDA explains, it doesn't verify compounded drugs' safety, effectiveness or quality before marketing. A licensed provider may still prescribe — that decision is between you and your doctor.
A licensed U.S. compounding pharmacy dispenses prescribed NAD+. Neither a prescription nor the NR blood findings establish a heart-failure benefit for that preparation.
What belongs in the provider's review?
The useful discussion starts with the treatment goal, current heart medicines, kidney and liver history, and evidence for the proposed preparation. The prescriber sets any actual dose and follow-up plan.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A clear explanation of what remains uncertain belongs in that conversation too.





